Braze, Inc.
BRZE Nasdaq Services-Prepackaged Software Financials FY2020βFY2026
What Braze, Inc. does
No business description yet.
- Legal name
- Braze, Inc.
- Fiscal year ends
- January 31, 2026
- Latest annual report
- 10-K Β· Mar 25, 2026
- Accession Β· CIK
- 0001676238-26-000013
0001676238
Revenue and margins
Braze, Inc. had $738M of revenue in fiscal 2026, up 24.4% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $61.9M in fiscal 2026, 8.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Braze, Inc. returned β to shareholders in fiscal 2026. The diluted share count rose 5.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Braze, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $514M | $68.6M | $68.2M | $83.1M | $124M |
| Current ratio | 3.8x | 2.7x | 2.1x | 2.0x | 1.4x |
| Quick ratio | 3.8x | 2.7x | 2.1x | 2.0x | 1.4x |
| Total assets | $666M | $705M | $811M | $871M | $1.1B |
| Total liabilities | $161M | $259M | $367M | $396M | $490M |
| Shareholders' equity | $502M | $445M | $444M | $475M | $624M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 4 / 8 | 3 / 8 | 5 / 8 | 5 / 8 | 3 / 8 |
| Accruals ratio | β | β15.0% | β9.9% | β17.0% | β17.9% | β16.7% | β20.4% |
| Altman Z'' | β | β3.74 | 5.83 | 2.16 | 0.65 | 0.53 | β0.77 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $96.4M | $150M | $238M | $355M | $472M | $593M | $738M |
| Gross profit | $60.7M | $95.7M | $160M | $240M | $324M | $410M | $496M |
| Research and development | $20.3M | $29.2M | $59.0M | $97.3M | $120M | $134M | $167M |
| Operating income | β$33.5M | β$32.2M | β$78.2M | β$148M | β$145M | β$122M | β$145M |
| Pretax income | β$31.4M | β$31.4M | β$78.3M | β$140M | β$128M | β$101M | β$128M |
| Income tax | $0.5M | $0.5M | β$0.2M | $0.6M | $2.0M | $3.4M | $2.6M |
| Net income | β$31.8M | β$31.8M | β$76.7M | β$139M | β$129M | β$104M | β$131M |
| Diluted EPS | β$1.96 | β$1.77 | β$2.20 | β$1.47 | β$1.32 | β$1.02 | β$1.22 |
| Diluted shares | 0.02B | 0.02B | 0.03B | 0.09B | 0.10B | 0.10B | 0.11B |
| Cash flow | |||||||
| Cash from operations | β$7.4M | β$6.1M | β$35.4M | β$22.3M | $6.9M | $36.7M | $71.4M |
| Capital expenditure | $1.7M | $2.5M | $2.3M | $15.4M | $9.8M | $13.2M | $9.6M |
| Free cash flow | β$9.1M | β$8.5M | β$37.7M | β$37.8M | β$2.9M | $23.4M | $61.9M |
| Depreciation and amortization | $0.6M | $1.6M | $2.8M | $4.6M | $7.0M | $10.1M | $19.3M |
| Stock-based compensation | $12.4M | $7.5M | $47.2M | $72.2M | $97.2M | $115M | $144M |
| Acquisitions | β | β | $0.0M | $0.0M | $16.3M | $0.0M | $182M |
| Share buybacks | $0.0M | $0.2M | $0.0M | $0.0M | $0.2M | β | β |
| Dividends and buybacks | $0.0M | $0.2M | $0.0M | $0.0M | $0.2M | β | β |
| Balance sheet | |||||||
| Cash and short-term investments | $11.6M | $86.5M | $514M | $68.6M | $68.2M | $83.1M | $124M |
| Current assets | β | $134M | $608M | $583M | $601M | $644M | $568M |
| Current liabilities | β | $101M | $160M | $217M | $289M | $324M | $420M |
| Property and equipment, net | β | $5.5M | $7.4M | $20.3M | $29.4M | $38.6M | $43.5M |
| Goodwill | β | β | β | $0.0M | $28.4M | $28.4M | $262M |
| Intangible assets | β | β | β | $0.5M | $3.7M | $3.1M | $61.5M |
| Total assets | β | $171M | $666M | $705M | $811M | $871M | $1.1B |
| Total liabilities | β | $103M | $161M | $259M | $367M | $396M | $490M |
| Preferred stock | β | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | β$86.9M | β$109M | $502M | $445M | $444M | $475M | $624M |
| Margins | |||||||
| Gross margin | 63.0% | 63.7% | 67.0% | 67.4% | 68.7% | 69.1% | 67.1% |
| Operating margin | β34.8% | β21.4% | β32.9% | β41.7% | β30.7% | β20.6% | β19.6% |
| EBITDA margin | β34.1% | β20.3% | β31.7% | β40.4% | β29.2% | β18.9% | β17.0% |
| Net margin | β33.0% | β21.1% | β32.2% | β39.1% | β27.4% | β17.5% | β17.8% |
| FCF margin | β9.4% | β5.7% | β15.8% | β10.6% | β0.6% | 4.0% | 8.4% |
| Returns | |||||||
| Return on capital employed | β | β45.8% | β15.4% | β30.4% | β27.7% | β22.4% | β20.9% |
| Return on equity | β | β | β39.0% | β29.4% | β29.0% | β22.6% | β23.9% |
| Return on assets | β | β18.5% | β18.3% | β20.3% | β17.0% | β12.3% | β13.2% |
| Return on tangible equity | β | β | β15.3% | β31.2% | β31.3% | β23.4% | β43.7% |
| Growth | |||||||
| Revenue growth | β | 55.9% | 58.5% | 49.3% | 32.7% | 25.8% | 24.4% |
| FCF growth | β | β | β | β | β | β | 163.8% |
| Share count change | β | 11.0% | 94.2% | 171.0% | 3.7% | 4.2% | 5.6% |
| Financial health | |||||||
| Current ratio | β | 1.3x | 3.8x | 2.7x | 2.1x | 2.0x | 1.4x |
| Quick ratio | β | 1.3x | 3.8x | 2.7x | 2.1x | 2.0x | 1.4x |
| Capital allocation | |||||||
| Capex / revenue | 1.8% | 1.6% | 1.0% | 4.3% | 2.1% | 2.2% | 1.3% |
| Stock comp / revenue | 12.9% | 5.0% | 19.8% | 20.3% | 20.6% | 19.4% | 19.5% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 4.0 | 3.0 | 5.0 | 5.0 | 3.0 |
| Altman Z'' | β | β3.7 | 5.8 | 2.2 | 0.7 | 0.5 | β0.8 |
| Accruals ratio | β | β15.0% | β9.9% | β17.0% | β17.9% | β16.7% | β20.4% |
Source: SEC EDGAR XBRL filings (CIK 0001676238). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.